Jason Abdou Mouabbi, MD

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Articles

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

December 5th 2025

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

December 5th 2025

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

December 5th 2025

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

December 5th 2025

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

December 5th 2025

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

December 5th 2025

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

December 5th 2025

A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

December 5th 2025

Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.

Dr Mouabbi on Data From the CompassHER2 pCR Trial in HER2+ Breast Cancer

September 9th 2025

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Dr Mouabbi on Areas for Further Investigation in HER2+ Breast Cancer

August 28th 2025

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Looking Ahead: The Future of MRD Testing and Breast Cancer Management and Insights From ASCO 2025

July 22nd 2025

Panelists note that detecting low-level circulating tumor DNA (ctDNA) despite normal imaging presents a clinical challenge, requiring personalized management that balances early intervention with patient-centered communication, as this molecular signal offers a valuable window to detect and treat microscopic disease before overt recurrence.

Clinical Implications of Ultrasensitive MRD Detection With Next-Gen ctDNA Assays

July 22nd 2025

Panelists highlight that advances in circulating tumor DNA (ctDNA) testing now enable detection of cancer at ultralow levels far earlier than traditional methods, offering new opportunities for timely intervention while emphasizing that negative results, though increasingly reliable, still require cautious interpretation to guide personalized treatment decisions.

Patient Selection and Implementation Strategies for MRD Testing

July 22nd 2025

Panelists emphasize that as circulating tumor DNA (ctDNA) testing becomes more integrated into clinical practice, careful interpretation, tailored testing schedules, and ongoing provider education are key to its effective use in personalized breast cancer care.

Applying ctDNA Insights to Real-World Decisions and Tumor Evolution

July 15th 2025

Panelists discuss the real-world challenges of managing patients with positive circulating tumor DNA (ctDNA) but no radiographic evidence of disease, emphasizing treatment intensification, genomic profiling for resistance mutations, dynamic monitoring, and the integration of ctDNA with imaging and biopsy to guide personalized breast cancer care.

Personalizing Posttreatment Care: Insights From DARE, LEADER , and Emerging MRD Trials

July 15th 2025

Panelists discuss ongoing studies exploring circulating tumor DNA (ctDNA) use in the adjuvant breast cancer setting to detect recurrence earlier and guide therapy, highlighting advances in assay sensitivity, the choice between tumor-informed and tumor-agnostic tests, and the challenge of turning ctDNA’s strong prognostic value into actionable, outcome-improving interventions.

Beyond Traditional Biomarkers: Prognostic Impact of ctDNA in the Posttreatment Setting

July 8th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a highly predictive prognostic biomarker in breast cancer, guiding personalized treatment intensification and informing important patient decisions while enhancing risk stratification and motivating proactive care despite ongoing research into its impact on long-term outcomes.

Monitoring Response in Real Time: ctDNA as a Predictive and Surrogate Marker in Early Treatment

July 8th 2025

Panelists discuss how circulating tumor DNA (ctDNA) is becoming a vital biomarker in breast cancer, with its dynamic changes guiding personalized treatment decisions, serving as a surrogate end point in trials, enabling earlier detection of progression, and offering a less-invasive monitoring tool that complements imaging—especially benefiting patients with hard-to-monitor disease or those who are frail.

Sequencing, Safety, and the Evolving Role of Oral SERDs in HR+/HER2– mBC

July 4th 2025

A panelist discusses how clinicians should exhaust all endocrine therapies plus targeted therapies before moving to chemotherapy or antibody-drug conjugates, while noting that different oral SERDs have varying adverse effect profiles that patients should be counseled about.

Oral SERDs in ER+/HER2– mBC: Current Data and Future Directions

July 4th 2025

A panelist discusses how the EMBER-3 study results cannot be directly compared to those from EMERALD because of different patient populations, with EMBER-3 having fewer heavily pretreated patients and different baseline characteristics.

Personalizing Early Breast Cancer Care: ctDNA Surveillance Insights From E-BLIS and I-SPY 2

July 1st 2025

Panelists discuss how emerging data from studies like E-BLIS and I-SPY 2 validate circulating tumor DNA (ctDNA) as a powerful prognostic tool in early breast cancer, showing it can detect recurrence months before imaging and potentially refine risk stratification beyond traditional markers, though its role in guiding treatment decisions remains under active investigation.